Viridian Therapeutics, Inc.
VRDN
$16.86
-$0.34-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -360.59M | -342.60M | -301.97M | -344.06M | -308.32M |
| Total Depreciation and Amortization | 464.00K | 460.00K | 163.00K | 483.00K | 512.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.24M | 42.72M | 33.70M | 29.08M | 27.36M |
| Change in Net Operating Assets | 15.50M | 23.03M | -57.86M | 5.44M | 701.00K |
| Cash from Operations | -303.39M | -276.39M | -325.97M | -309.06M | -279.75M |
| Capital Expenditure | -432.00K | -495.00K | -369.00K | -535.00K | -597.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -59.93M | -37.07M | 239.31M | 28.73M | 15.05M |
| Cash from Investing | -60.36M | -37.56M | 238.94M | 28.20M | 14.46M |
| Total Debt Issued | 28.88M | 28.88M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 363.93M | 366.99M | 58.08M | 282.19M | 281.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 25.00M | 25.00M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31.09M | 30.88M | -1.73M | -16.67M | -16.77M |
| Cash from Financing | 423.89M | 426.74M | 56.36M | 290.52M | 289.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.13M | 112.79M | -30.67M | 9.66M | 24.57M |